The Business Research Company’s report on the Therapeutic BCG Vaccines Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the therapeutic bcg vaccines industry?
The rising number of tuberculosis (TB) cases worldwide will propel the growth of the therapeutic BCG vaccine market going forward. Tuberculosis (TB) is an infectious illness that can be potentially dangerous and primarily impacts the lungs. People can contract tuberculosis from one another by coughing or sneezing small droplets of bacteria into the air. BCG vaccines are used to stimulate the immune system to fight infection but do not cause TB since the germs are weak. It consistently offers protection against the most dangerous types of TB, such as adolescent TB meningitis. The BCG vaccine protects against tuberculosis which helps to fight against infection, hence the usage of therapeutic BCG vaccines increased. For instance, in February 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, tuberculosis (TB) cases in England increased by 10.7% in 2023, with 4,850 cases reported compared to 4,380 in 2022 . Therefore, the rising number of tuberculosis (TB) cases worldwide is driving the growth of the therapeutic BCG vaccine market.
Access Your Free Sample of the Global Therapeutic BCG Vaccines Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=9178&type=smp
What is the estimated market size of the therapeutic bcg vaccines sector by 2029, based on current forecasts?
The therapeutic bcg vaccines market size has grown strongly in recent years. It will grow from $56.47 billion in 2024 to $59.66 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to government initiatives for tb control, immune system modulation, global immunization programs, treatment of bladder cancer, investments in vaccine manufacturing, emergence of drug-resistant tb strains.
The therapeutic bcg vaccines market size is expected to see strong growth in the next few years. It will grow to $77.17 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to expansion to other indications, increased research on immunotherapy, global efforts against emerging infectious diseases, regulatory support for vaccine development, focus on tuberculosis elimination. Major trends in the forecast period include advancements in vaccine technology, supply chain optimization, market consolidation and partnerships, patient education and awareness, alternative delivery methods, personalized medicine approaches.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=9178&type=smp
#Who are the top players in the therapeutic bcg vaccines market?
Major companies operating in the therapeutic bcg vaccines market include Merck & Co Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited, Statens Serum Institute, AJ Vaccines, Bul Bio-National Center of Infectious and Parasitic Diseases Ltd, Biomed Lublin S.A., Microgen, Taj Pharma Ltd., PT Bio Farma, Torlak Institute of Virology, Bacille Bilie Calmette-Guerin Laboratory, China Biotechnology Co Ltd., Bharat Biotech International Ltd., Biological E. Limited, Shanghai Institute of Biological Products Co. Ltd., Cipla Limited, Instituto Butantan
#What are the major trends in the therapeutic bcg vaccines market?
Strategic partnerships have emerged as a key trend gaining popularity in the therapeutic BCG vaccine market. Major companies operating in the therapeutic BCG vaccine market are focused on collaborating with other key players to sustain their position in the market. For instance, in May 2024, ImmunityBio, a US-based biotechnology company, partnered with Serum Institute of India, an India-based biotechnology and biopharmaceuticals company, to secure a supply of the Bacillus Calmette-Guerin (BCG) vaccine for all cancer types. The partnership focuses on producing the standard BCG (sBCG) approved for use outside the US and a next-generation recombinant BCG (iBCG) currently undergoing tests. iBCG is intended for use along with ImmunityBio’s ANKTIVA (nogapendekin alfa inbakicept-PMLN) for approved and additional future indications, contingent on regulatory approvals.
Which geography holds the highest therapeutic bcg vaccines market share?
Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2024. The regions covered in the therapeutic bcg vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report
How do different segments contribute to the overall expansion of the therapeutic bcg vaccines market?
The therapeutic bcg vaccines market covered in this report is segmented –
1) By Type: Therapy BCG, Immune BCG
2) By Demographics: Pediatrics, Adults
3) By End Use: Hospitals, Clinics, Other End Users
Subsegments:
1) By Therapy BCG: Intravesical BCG, Injectable BCG
2) By Immune BCG: BCG For Immune Enhancement, BCG For Allergy Treatment
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9178
How is the therapeutic bcg vaccines market defined?
Therapeutic BCG vaccine refers to a vaccine that offers defense against TB, also referred to as tuberculosis. The therapeutic BCG vaccine, which stands for the Bacillus Calmette-Guérin vaccine, is not a part of the standard NHS vaccination schedule. Only one dose of the BCG vaccine should be administered in a lifetime.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
